Chemical reagents maker Alpha Teknova beats Q4 revenue expectations

Alpha Teknova

26/02/2026 21:27

Overview

Reagent producer's Q4 revenue rose 8% yr/yr, beating analyst expectations

Adjusted EBITDA loss for Q4 narrowed significantly from last year

Company forecasts 2026 revenue of $42-44 mln

Outlook

Company anticipates 2026 revenue of $42-44 mln

Teknova expects Free Cash Outflow under $10 mln in 2026

Company aims to be Adjusted EBITDA positive by end of 2027

Result Drivers

CLINICAL SOLUTIONS GROWTH - Q4 2025 Clinical Solutions revenue increased by 47% compared to Q4 2024, contributing to overall revenue growth

MANUFACTURING EFFICIENCY - Improved manufacturing efficiency drove Q4 2025 gross margin to 32.5%, up from 23.0% in Q4 2024

OPERATING EXPENSES REDUCTION - Operating expenses decreased due to reduced general and administrative spending, despite increased sales and marketing investment

Company press release: ID:nGNX2QZCWk

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$9.98 mln
$9.72 mln (6 Analysts)
Q4 EPS
-$0.09
Q4 Net Income
-$4.76 mln
Q4 Free Cash Flow
-$800,000
Q4 Gross Profit
$3.24 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Alpha Teknova Inc is $8.00, about 254% above its February 25 closing price of $2.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)